American Journal of Cancer

, Volume 1, Issue 5, pp 341–348 | Cite as

90Y Ibritumomab Tiuxetan

  • Christopher I. CarswellEmail author
  • Lynda R. Wiseman
Adis New Drug Profile


90Yttrium (90Y) ibritumomab tiuxetan is a radiolabeled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumor activity as a result of emission of β particles. It is administered as part of a therapeutic regimen which includes rituximab, a monoclonal antibody which produces antibody-dependent cell-and complement-mediated cytotoxicity.

90Y ibritumomab tiuxetan, when given as part of the recommended regimen, produced significantly higher overall (80 vs 56%: p = 0.002) and complete response rates (30 vs 16%: p = 0.04) than rituximab alone in a randomized nonblind study in patients with relapsed or refractory low-grade, follicular or transformed non-Hodgkin’s lymphoma (NHL). Quality of life, as measured by the Functional Assessment of Cancer Therapy-General survey, was also improved significantly (from baseline to week 12; p = 0.001) in recipients of ibritumomab tiuxetan but not in rituximab recipients.

▴ In a noncomparative trial in patients with follicular NHL refractory to rituximab, the ibritumomab tiuxetan therapeutic regimen produced overall and complete response rates of 74 and 15%, respectively.The Kaplan-Meier median estimates of the time to progression and duration of response were 6.8 and 6.4 months, respectively.

▴ The dose-limiting toxicity of ibritumomab tiuxetan is reversible myelosuppression which was seen in most patients. Most non-hematological toxicity was mild or moderate.


Features and properties of 90Y Ibritumomab Tiuxetan


90Y Ibritumomab Tiuxetan


Complete Response Rate Bone Marrow Involvement Nonhematological Toxicity Unlabeled Antibody Ibritumomab Tiuxetan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999 Jul; 58: 79–88PubMedCrossRefGoogle Scholar
  2. 2.
    Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin’s lymphoma.CurrPharmBiotechnol 2001 Dec; 2(4): 341–9Google Scholar
  3. 3.
    Alcindor T, Witzig TE. Radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol 2002 Aug; 3(4): 275–82PubMedCrossRefGoogle Scholar
  4. 4.
    DeNardo GL, O’Donnell RT, Oldham RK, et al. A revolution in the treatment of non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 1998; 13(4): 213–23PubMedCrossRefGoogle Scholar
  5. 5.
    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immu-notherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002 May 15; 20(10): 2453–63PubMedCrossRefGoogle Scholar
  6. 6.
    Wun T, Kwon DS, Tuscano JM. Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin’s lymphoma. Biodrugs 2001; 15(3): 151–62PubMedCrossRefGoogle Scholar
  7. 7.
    Bush S. Monoclonal antibodies conjugated with radioisotopes for the treatment of non-Hodgkin’s lymphoma. Semin Oncol Nurs 2002 Feb; 18(1 Suppl. 1): 16–21PubMedCrossRefGoogle Scholar
  8. 8.
    Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999 Sep; 11: 375–80PubMedCrossRefGoogle Scholar
  9. 9.
    IDEC Pharmaceuticals Corporation. Zevalin: product information. San Diego (CA): IDEC Pharmaceuticals Corporation, 2002 JanGoogle Scholar
  10. 10.
    Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-1 abeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2(3): 457–70PubMedGoogle Scholar
  11. 11.
    Wiseman GA, Gordon LI, Witzig TE, et al. Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of T cells or natural killer cells [abstract]. Blood 2000 Nov 16; 96 (Pt 2): 252Google Scholar
  12. 12.
    Chinn PC, Leonard JE, Rosenberg J, et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin’s lymphoma. Int J Oncol 1999 Nov; 15(5): 1017–25PubMedGoogle Scholar
  13. 13.
    Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 2001 Jul; 39: 181–94PubMedCrossRefGoogle Scholar
  14. 14.
    Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999 Dec; 17(12): 3793–803PubMedGoogle Scholar
  15. 15.
    Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000 Jul; 27(7): 766–77PubMedCrossRefGoogle Scholar
  16. 16.
    Wiseman GA, Leigh BR, Czuczman MS, et al. The pharmacokinetic profile of Zevalin TM is similar when radiolabeled with 90Y from different suppliers [abstract]. Blood 2001 Nov 16; 98 (Pt 2): 254Google Scholar
  17. 17.
    Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002 Feb 15; 94(4 Suppl.): 1349–57PubMedCrossRefGoogle Scholar
  18. 18.
    IDEC Pharmaceuticals. Product: Zevalin [online]. Available from URL: [Accessed 2002 May 13]
  19. 19.
    Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002 Jun 15; 99(12): 4336–42PubMedCrossRefGoogle Scholar
  20. 20.
    Witzig TE, White CA, Flinn IW, et al. Zevalin (TM) radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma [abstract]. Blood 2000 Nov 16; 96 (Pt 1): 507Google Scholar
  21. 21.
    Witzig TE. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin’s lymphoma. Semin Oncol 2000 Dec; 27(6 Suppl. 12): 74–8PubMedGoogle Scholar
  22. 22.
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas: NCI Sponsored International Working Group [abstract]. J Clin Oncol 1999 Apr; 17(4): 1244PubMedGoogle Scholar
  23. 23.
    Witzig T, White CA, Wiseman G, et al. IDEC-Y2B8 radioimmunotherapy: responses in patients with splenomegaly [abstract]. Blood 1998 Nov 15; 92 (Pt 1 Suppl. 1): 417Google Scholar
  24. 24.
    Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002 Aug 1; 20(15): 3262–9PubMedCrossRefGoogle Scholar
  25. 25.
    Harris NL, Jaffe ES, Stein H, et al. A revised Europe an-American classification of lymphoid neoplasms: a proposal fromme International Lymphoma Study Group. Blood 1994 Sep 1; 84(5): 1361–92PubMedGoogle Scholar
  26. 26.
    Emmanoulidies C, Witzig T, Gordon L, et al. Zevalin radioimmunotherapy is safe and effective in geriatric patients with low grade, follicular or CD20+ transformed non-Hodgkin’s lymphoma [plus poster]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco, 286Google Scholar
  27. 27.
    Schilder R, Witzig T, Gordon L, et al. Zevalin radioimmunotherapy for low grade, follicular, and Cd20+ transformed non-Hodgkin’s lymphoma is effective even in patients with mild thrombocytopena and poor prognostic factors. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco, 236Google Scholar
  28. 28.
    Witzig TE, Gordon L, Gaston I, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype [abstract]. Proc ASCO 2002; 21: 1063aGoogle Scholar
  29. 29.
    Bartlett NL, Witzig TE, Gordon L, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B cell non-Hodgkin’s lymphoma (NHL) patients [abstract]. Proc ASCO 2002; 21: 51aGoogle Scholar
  30. 30.
    Gordon LI, Witzig TE, Emmanouilides CE, et al. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin’s lymphoma: analysis of response and toxicity [abstract]. Proc ASCO 2002 May; 21 (Pt 1): 1061aGoogle Scholar
  31. 31.
    Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Zevalin TM for non-Hodgkin lymphoma. Blood 2001 Nov 16; 98 (Pt 1): 604–5CrossRefGoogle Scholar
  32. 32.
    Czuczman MS, Emmanouilides CE, Witzig TE, et al. Multivariate analysis of prognostic factors correlated with response to Y90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkins lymphoma [abstract]. Proc ASCO 2002; 21: 1062aGoogle Scholar
  33. 33.
    Witzig TE, White CA, Gordon LI, et al. Zevalin TM radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin’s lymphoma [abstract]. Blood 2001 Nov 16; 98 (Pt 1): 606Google Scholar
  34. 34.
    D’Orazio AI, Fisher MD. Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma and chronic lymphocytic leukemia. Clin Lymphoma 2001; 2(3): 139–44PubMedCrossRefGoogle Scholar
  35. 35.
    Wiseman GA, Leigh BR, Witzig TE, et al. Family members of patients receiving Zevalin TM radioimmunotherapy do not receive radiation exposure above background levels. Blood 2001 Nov 16; 98 (Pt 2): 236–7Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Adis International Inc.LanghorneUSA

Personalised recommendations